<DOC>
	<DOCNO>NCT01705197</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy Avanafil treatment erectile dysfunction moderate severe subject . And , additionally confirm efficacy safety initiate treatment Avanafil 100mg later increase 200mg , compare continue treatment Avanafile 100mg , subject .</brief_summary>
	<brief_title>This Study Evaluate Safety Efficacy Avanafil Treatment Erectile Dysfunction .</brief_title>
	<detailed_description>All subject , judge suitable clinical trial 4-week free run-in period complete , administer Avanafil 100mg ( study group ) placebo 100mg ( control group ) first 4 week randomization . When moderate severe adverse event 4 week evaluation administration , decide researcher effect Avanafil placebo 100mg erectile dysfunction insufficient , dosage increase 200mg execute . For subject sufficient improvement effect ED 100mg , dosage increase allow , previous 100mg administration maintain termination study .</detailed_description>
	<mesh_term>Erectile Dysfunction</mesh_term>
	<criteria>1 . Male patient 20 year old history erectile dysfunction least 6 month prior participation study 2 . Patients stable relationship 1 female partner 3 . Patients whose sex partner pregnancy lactating , take proper contraceptive 4 . Patients voluntarily decide participate clinical trial , sign informed consent form 5 . Patients whose failure rate sexual intercourse 50 % attempt sexual intercourse 3 different day ( once/day ) least 4week Free runin period 6 . Patients whose EF domain score le 18 point ( moderate severe erectile dysfunction ) IIEF questionnaire 4week Free runin period 1 . Patients spinal injury radical prostatectomy 2 . Patients anatomical malformation penis ( example : angulation , fibrosis corpus cavernosum , peyronies disease , etc . ) 3 . Patients surgery pelvic cavity within 6 month prior participation study 4 . Patients neurogenic endocrine ( example : hyperprolactinemia , low testosterone , etc . ) ED Hyperprolactinemia : Serum prolactin ≥ 3 X ULN Low testosterone : Total testosterone less normal low limit ( testosterone susceptible daily change , enrollment permit retesting 11 , limit , number 20 % less normal low limit . ) 5 . Patients major refractory psychiatric disorder ( include major depression schizophrenia ) significant neurological abnormality ( neurovascular disease ) 6 . Patients alcohol addiction persistent abuse drug dependence 7 . Patients hepatic dysfunction renal dysfunction per follow : Hepatic dysfunction : AST , ALT ≥ 3 X ULN Renal dysfunction : Serum creatinine ＞ 2.0mg/dL 8 . Diabetic patient whose HbA1c exceed 12 % 9 . Patients proliferative diabetic retinopathy 10 . Patients stroke , TIA ( Transient ischemic attack ) , MI ( Myocardial Infarction ) fatal arrhythmia , severe heart failure , unstable angina underwent coronary artery bypass grafting ( CABG ) within last 6 month prior participation study 11 . Patients hypotension ( rest SBP/DBP sit position le 90/50mmHg ) unregulated hypertension ( rest SBP/DBP sit position exceeds 170/100mmHg ) 12 . Patients hematopathy , predisposition priapism ( sicklecell disease , multiple myeloma , leukemia ) 13 . Patients know genetically degenerative retinopathy , include retinitis pigmentosa 14 . Patients experience avanafil , viagra , cialis , levitra , yaila , zydena , mvix ED treatment within 2 week participation study 15 . Patients administer following medication : Nitrate/Nitric oxide ( NO ) donor ( example : nitroglycerin , isosorbide mononitrate , amyl nitrate/nitrite , sodium nitroprusside ) Androgens ( example : testosterone ) , antiandrogen , trazodone Anticoagulant ( antiplatelet agent exclude ) Agents significantly affect CYP450 3A4 intermediary metabolism , erythromycin , intraconazol , ketoconazol , cimetidine , ritonavir , saquinavir , amprenavir , indinavir , nelfinavir , etc . 16 . Patients history hypersensitivity PDE5 inhibitor respond 17 . Patients primary hyposexuality 18 . Patients take investigational product within 4 week study 19 . For reason besides aforementioned case , patient whose participation deem inappropriate due clinically significant finding accord medical decision principal investigator study personnel</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>